INKT MiNK Therapeutics Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of minktherapeutics.com (INKT)

MiNK Therapeutics, Inc. (INKT) is developing an innovative iNKT therapy platform across US centers. The EV-to-revenue ratio illustrates the market response, while the 168500.00 metric confirms the current level. Pipeline diversification across solid and hematological tumors mitigates failure risks. Patents and strict FDA oversight protect the business, creating high barriers to entry for new players in the sector.

Company Value to Revenue: MiNK Therapeutics Inc. (INKT) for 11/23/2025 - 11/21/2026

minktherapeutics.com - analytical breakdowns and key metrics (INKT)

- share price and consensus valuation forecast:
Initial company analysis:MiNK Therapeutics, Inc. INKT
Product sample of MiNK Therapeutics, Inc.

For the biotechnology sector, where MiNK Therapeutics, Inc. (INKT) is developing innovative allogeneic iNKT cell-based therapy, this indicator serves as a tool for assessing the business's market value relative to its operational efficiency. By analyzing the EV/Sales multiple chart, an investor can see the ratio of enterprise value (market capitalization plus debt minus cash) to revenue, which allows for an assessment of the fundamental value of the unique cancer-fighting platform without distortions from debt load.

Competitor analysis for MiNK Therapeutics, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP